CBB-120 / Eli Lilly - LARVOL DELTA

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates (Businesswire) - "The company is focused on advancing next-generation ADCs with the potential to transform clinical practice. Its lead candidate, CBB-120, is a TROP2-targeting TOP1i/ATRi dual-payload ADC for cancer treatment. It is designed to enhance the therapeutic index and generate more durable responses compared to current TROP2-targeting ADCs, while also addressing key resistance mechanisms. U.S. Food and Drug Administration Investigational New Drug application for CBB-120 is anticipated in 2026....Under the terms of the agreement, Lilly will acquire CrossBridge Bio, and CrossBridge Bio shareholders could receive up to $300 million in cash, inclusive of an upfront payment and a subsequent payment upon achieving a specified development milestone."

IND • Licensing / partnership • Solid Tumor

CrossBridge Bio Awarded $15 Million CPRIT Grant to Advance CBB-120, Its Lead Dual-Payload ADC Targeting TROP-2, Into the Clinic (Businesswire) - "The award will support completion of IND-enabling activities and advancement of CBB-120, the company’s lead TROP-2 targeted TOP1i/ATRi dual-payload ADC, into first-in-human studies....The CPRIT award will enable CrossBridge Bio to complete GLP toxicology studies, scale up manufacturing, finalize analytical development, and prepare for an IND filing in 2026."

Financing • IND • Solid Tumor

CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates (AACR-NCI-EORTC 2025) - "Among current therapies, Trodelvy® and Datroway® (Dato-DXd) carrying topoisomerase I inhibitors (Top1i) have demonstrated notable clinical benefits. CBB-120, a novel site-specific Fc-silenced dual-payload ADC targeting TROP2, enables targeted delivery of both its Top1i and ATRi payloads to TROP2-expressing tumors, achieving synergistic, highly potent anti-tumor efficacy while minimizing systemic toxicity. Our findings support the continued development of CBB-120 as a promising best-in-class next-gen ADC for TROP2-positive cancers. Our data also emphasizes the improved safety profile of our EGCit linker payload platform, which can be used to address unmet needs in other important tumor types."

Preclinical • Breast Cancer • Endometrial Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2

CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies (Businesswire) - "CrossBridge Bio...announced the closing of a $10 million seed financing led by TMC Venture Fund and CE-Ventures, the corporate venture capital platform of Crescent Enterprises, with participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors....The seed capital will fund the development of the company’s lead program, CBB-120, a potential best-in-class TROP-2 dual-payload ADC for the treatment of solid tumors, and accelerate the expansion of its pipeline of novel ADC programs. Additionally, funds will be used to further derisk the company’s proprietary linker technology with dual-payload applications, a critical component of its ADC platform, to improve the safety and efficacy profiles of its current and future drug candidates."

Financing • Oncology • Solid Tumor